The FDA on 11 September 2013 approved a new use for Botox Cosmetic (onabotulinumtoxinA) from Allergan, for the temporary improvement...
Allergan presented the results of its HARMONY study, which assessed the overall impact and psychological benefits of multimodal injectable and...
Allergan Aesthetics, an AbbVie company announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase III clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment.
Allergan Aesthetics, an AbbVie company announced positive topline results from the second of three Phase III clinical studies evaluating onabotulinumtoxinA (Botox Cosmetic) for the treatment of moderate to severe platysma prominence associated with platysma muscle activity (M21-310).